Cytogen, Inc.

Equities

A217330

KR7217330000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 08/05/2024 BST			5-day change	1st Jan Change
11,250 ^KRW	-1.23%		-2.93%	-16.79%

03-20	Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	CI
03-18	Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	CI

Candx Holdings Limited agreed to acquire a 31.96% stake in Cytogen, Inc. from Jeon Byung Hee and others for KRW 110 billion

December 18, 2023

Candx Holdings Limited agreed to acquire a 31.96% stake in Cytogen, Inc. (KOSDAQ:A217330) from Jeon Byung Hee and others for KRW 110 billion on December 19, 2023. Transaction is financed through it's own funds.

Latest news about Cytogen, Inc.

Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	03-19	CI
Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	03-17	CI
Cytogen, Inc. announced that it has received KRW 55.49999 billion in funding from CanDx Holdings Limited	12-27	CI
Cytogen, Inc. announced that it expects to receive KRW 99.999821616 billion in funding from Candx Holdings Limited	12-27	CI
Candx Holdings Limited agreed to acquire a 31.96% stake in Cytogen, Inc. from Jeon Byung Hee and others for KRW 110 billion	12-18	CI
Cytogen, Inc. announces tranche update	26/10/23	CI
Cytogen Raising KRW10 Billion to Finance Operations	27/09/23	MT
Cytogen, Inc. announced that it expects to receive KRW 69.99999 billion in funding from Excelsior Capital Korea Limited	25/09/23	CI
Cytogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/03/23	CI
Cytogen, Inc.(KOSDAQ:A217330) added to S&P Global BMI Index	20/09/21	CI
TSD Life Sciences Co.,Ltd. announced that it has received KRW 2.9999853 billion in funding from Cytogen, Inc.	20/05/21	CI
TSD Life Sciences Co.,Ltd. announced that it has received KRW 2.9999853 billion in funding from Cytogen, Inc.	20/05/21	CI
Cytogen, Inc. announced that it has received KRW 30 billion in funding	19/05/21	CI
Cytogen, Inc. announced that it expects to receive KRW 30 billion in funding	16/05/21	CI
TSD Life Sciences Co.,Ltd. announced that it expects to receive KRW 2.9999853 billion in funding from Cytogen, Inc.	16/05/21	CI
Cytogen, Inc. announced that it has received KRW 10 billion in funding	24/09/20	CI
Cytogen, Inc. announced that it expects to receive KRW 10 billion in funding	03/09/20	CI
Well Marker Bio Co., Ltd. announced that it has received KRW 18 billion in funding from a group of investors	07/07/19	CI
Cytogen, Inc. has completed an IPO in the amount of KRW 20.4 billion.	21/11/18	CI
Cytogen, Inc. has filed an IPO.	20/02/18	CI
Cytogen, Inc. has withdrawn its IPO.	19/02/18	CI
Cytogen, Inc. has filed an IPO.	08/10/15	CI

Chart Cytogen, Inc.

Duration

Period

More charts

Company Profile

Cytogen Inc is a Korea-based company mainly engaged in the provision of liquid biopsy application services. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The Company distributes its products within the domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

12/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
CYTOGEN, INC.	-16.79%	187M
EXACT SCIENCES CORPORATION	-26.13%	10.94B
IOVANCE BIOTHERAPEUTICS, INC.	+64.27%	3.75B
GUARDANT HEALTH, INC.	-29.46%	2.27B
BGI GENOMICS CO., LTD.	-10.06%	2.25B
VERACYTE, INC.	-25.92%	1.54B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+52.54%	1.18B
SEEGENE, INC.	-2.84%	754M
CAREDX, INC	-9.50%	529M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.69%	469M

Bio Diagnostics & Testing